Dr. Villaflor on RAVD of Radiotherapy With Induction Chemotherapy in HNSCC
In Partnership With:
Victoria M. Villaflor, MD, medical oncologist, associate professor of medicine, The University of Chicago Medicine, discusses findings from a response-adapted volume de-escalation of radiotherapy using induction chemotherapy in locally advanced head and neck squamous cell cancer.
Victoria M. Villaflor, MD, medical oncologist, associate professor of medicine, The University of Chicago Medicine, discusses findings from a response-adapted volume de-escalation (RAVD) of radiotherapy (RT) using induction chemotherapy (IC) in locally advanced head and neck squamous cell cancer (LA-HNSCC).
Results from the study showed that overall survival at 2 years was 80.8%, while disease-free and progression-free survival at 2 years was slightly lower at 79.1%, Villaflor explains. Researchers noted that 86% of patients experienced a good response and disease-free survival (DFS) at 2 years.
There were no patients who experienced failure outside the radiation targeted area, Villaflor says. These results are leading researchers to examine RAVD in patients with HPV-positive oropharyngeal cancer. Within this subgroup, researchers may be able to de-escalate volume for better long-term quality of life.
